I think you may overestimate what is "priced in".
BOT at 250mil MC with no fda approval does not get a look from fund managers. It is completely off their screens.
BOT at 1Bil MC with a recent fda approval, strong management and preparing for positive cashflow is a much different animal and meets criteria that more of the market can invest in.
Post-FDA decision price sweep, page-63
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 38.0¢ | $141.3K | 371.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 199331 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 20676 | 2 |
View Market Depth
| Last trade - 10.12am 01/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |